Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Relief Therapeutics Holding AG    RLF   CH0100191136

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about RELIEF THERAPEUTICS HOLDING AG
01/21Relief Therapeutics Signs $56 Million Share Subscription Facility With Shareh..
MT
01/21RELIEF THERAPEUTICS : Announces Implementation of New Share Subscription Facilit..
PU
01/21EQS-NEWS : Relief Announces Implementation of New Share Subscription Facility wi..
DJ
01/20GLOBAL MARKETS LIVE: Jack Ma reappears, Better-than-expected profits for Morg..
01/20Relief Therapeutics Stock Gains 6% on $55 Million Deal to Acquire AdVita Life..
MT
01/20RELIEF THERAPEUTICS : and AdVita Sign Binding Term Sheet for to Acquire All Shar..
PU
01/20EQS-NEWS : Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All S..
DJ
01/11RELIEF, NEURORX AND QUANTUM LEAP ANN : aviptadil) in the I-SPY COVID-19 Trial
PU
01/11NeuroRx, RELIEF THERAPEUTICS Signs Contract To Include COVID-19 Drug In I-SPY..
MT
01/11EQS-NEWS : Relief, NeuroRx and Quantum Leap announce the inclusion of ZYESAMI(TM..
DJ
01/11NEURORX, RELIEF, AND QUANTUM LEAP AN : aviptadil) in the I-SPY COVID-19 Trial
PR
01/11EQS-NEWS : Relief, NeuroRx and Quantum Leap -2-
DJ
2020RELIEF THERAPEUTICS : stock plunges after FDA rejects COVID-19 emergency approva..
RE
2020Relief Therapeutics, NeuroRx Finish Enrollment for COVID-19 Treatment Trial
MT
2020RELIEF THERAPEUTICS : and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial ..
PU
2020NEURORX : and Relief Conclude Enrollment in their Phase 2b/3 Trial of RLF-100&tr..
PR
2020EQS-NEWS : Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of R..
DJ
2020Relief Therapeutics Names Chief Commercial Officer
MT
2020RELIEF THERAPEUTICS : Appoints Chris L.J.J. Stijnen as Chief Commercial Officer
PU
2020EQS-NEWS : Relief Appoints Chris L.J.J. Stijnen as Chief Commercial Officer
DJ
2020RELIEF THERAPEUTICS : Announces Results of Extraordinary General Meeting of THER..
PU
2020RELIEF THERAPEUTICS : Announces Results of Extraordinary General Meeting of THER..
EQ
2020EQS-NEWS : Relief Announces Results of Extraordinary General Meeting of RELIEF T..
DJ
2020GLOBAL MARKETS LIVE: MasterCard, Volkswagen, Goldman Sachs…
2020Relief Therapeutics, NeuroRx Meet Patients Enrollment Target in Study of COVI..
MT
2020RELIEF THERAPEUTICS : and NeuroRx Meet 165 Patient Enrollment Target in Phase 2b..
PU
2020EQS-NEWS : Relief Therapeutics and NeuroRx Meet -2-
DJ
2020EQS-NEWS : Relief Therapeutics and NeuroRx Meet 165 Patient Enrollment Target in..
DJ
2020CORRECTION : NeuroRx and Relief announce initial successful results from expande..
PU
2020CORRECTION : NeuroRx and Relief announce initial successful results from expande..
EQ
2020EQS-NEWS : Correction: NeuroRx and Relief announce -2-
DJ
2020EQS-NEWS : Correction: NeuroRx and Relief announce initial successful results fr..
DJ
2020NEURORX AND RELIEF ANNOUNCE INITIAL : 72% survival seen in ICU patients
PR
2020NEURORX AND RELIEF ANNOUNCE INITIAL : 72% survival seen in ICU patients
PU
2020NEURORX AND RELIEF ANNOUNCE INITIAL : 72% survival seen in ICU patients
EQ
2020RELIEF THERAPEUTICS : Announces Notice of Extraordinary General Meeting of THERA..
PU
2020RELIEF THERAPEUTICS : Announces Notice of Extraordinary General Meeting of THERA..
EQ
2020Relief Therapeutics Hires Clinical Researcher for European Trial of COVID-19 ..
MT
2020RELIEF THERAPEUTICS : Selects CRO and CDMO for RLF-100TM in Europe
PU
2020RELIEF THERAPEUTICS : Selects CRO and CDMO for RLF-100TM in Europe
EQ
2020NEURORX : and Relief Therapeutics announce enrollment of 150 patients in phase 2..
PR
2020Relief Therapeutics, NeuroRx Register 150 Patients in Clinical Trial for COVI..
MT
2020RELIEF THERAPEUTICS : with Partner NeuroRx, Announces Enrollment of 150 Patients..
PU
2020RELIEF THERAPEUTICS : with Partner NeuroRx, Announces Enrollment of 150 Patients..
EQ
2020RELIEF THERAPEUTICS : pushes back data release date for COVID-19 study to Januar..
RE
2020RELIEF THERAPEUTICS AND NEURORX ANNO : Trial is on track to complete enrollment ..
PU
2020NEURORX AND RELIEF THERAPEUTICS ANNO : Trial is on track to complete enrollment ..
PR
2020RELIEF THERAPEUTICS AND NEURORX ANNO : Trial is on track to complete enrollment ..
EQ
2020RELIEF THERAPEUTICS : Appoints J. Paul Waymack, M.D., Sc.D. as Consultant to Str..
PU
2020RELIEF THERAPEUTICS : Appoints J. Paul Waymack, M.D., Sc.D. as Consultant to Str..
EQ
2020RELIEF THERAPEUTICS : NeuroRx and Relief announce topline efficacy data from pat..
PU
2020RELIEF THERAPEUTICS : says some COVID-19 patients who got its drug survived long..
RE
2020NEURORX : and Relief announce topline efficacy data from patients treated with R..
PR
2020RELIEF THERAPEUTICS : NeuroRx and Relief announce topline efficacy data from pat..
EQ
2020RELIEF THERAPEUTICS : Appoints Industry Veteran, Jack Weinstein, as Chief Financ..
EQ
2020RELIEF THERAPEUTICS : NeuroRx and Relief Therapeutics Establish Supply and Distr..
EQ
2020RELIEF THERAPEUTICS : Announces Capital Increase from its Final Tranche of the S..
PU
2020RELIEF THERAPEUTICS : deal with biggest owner lifts cash to $52 mln for COVID-19..
RE
2020RELIEF THERAPEUTICS : deal with biggest owner lifts cash to $52 mln for COVID-19..
RE
2020RELIEF THERAPEUTICS : Announces Capital Increase from its Final Tranche of the S..
EQ
2020New Covid-19 vaccine developments
2020RELIEF THERAPEUTICS : partner NeuroRx submits request for Emergency Use Authoriz..
PU
2020RELIEF THERAPEUTICS : partner NeuroRx submits request for Emergency Use Authoriz..
EQ
2020NEURORX : submits request for Emergency Use Authorization for RLF-100™ (av..
PR
2020UBS eying new acquisition, Deutsche Bank’s suspicious transactions…
2020RELIEF THERAPEUTICS : and NeuroRx Announce Partnership for Global Commercializat..
PU
2020RELIEF THERAPEUTICS : and NeuroRx Announce Partnership for Global Commercializat..
PR
2020RELIEF THERAPEUTICS : and NeuroRx Announce Partnership for Global Commercializat..
EQ
2020RELIEF THERAPEUTICS : Condensed consolidated interim financial statements for th..
PU
2020RELIEF THERAPEUTICS : Reports Half-Year 2020 Results
PU
2020RELIEF THERAPEUTICS : sees top-line trial results for COVID-19 treatment in earl..
RE
2020RELIEF THERAPEUTICS : Reports Half-Year 2020 Results
EQ
2020RELIEF THERAPEUTICS : Appoints Gilles Della Corte, M.D. as Chief Medical Officer
PU
2020RELIEF THERAPEUTICS : Appoints Gilles Della Corte, M.D. as Chief Medical Officer
EQ
2020RELIEF THERAPEUTICS : Announces Successful Up-listing from OTC Pink to OTCQB and..
PU
1  2  3Next